NantWorks Exercises Warrants for $3.9 Million

PDS Biotechnology issued 17,699,115 shares of common stock or pre-funded warrants to NantWorks at $0.22 per share.

Updated on Nov. 10, 2026 in Tech

Bold flat-color editorial illustration of a tall stack of cream and slate geometric discs, one split into two connected discs, set against a deep red field.
NantWorks exercised warrants to buy 17,699,115 PDS Biotechnology shares at $0.22 each, bringing roughly $3.9 million to the Princeton, N.J., cancer-immunotherapy company. AI Illustration. Upload story photo >

NantWorks exercised warrants to purchase 17,699,115 shares of PDS Biotechnology common stock or pre-funded warrants in lieu thereof, bringing approximately $3.9 million in gross proceeds to the Princeton, N.J.-based company. The warrants were issued in connection with a private placement that initially closed on September 14, 2026.

Why it matters

The exercise adds capital to a clinical-stage biotech company developing cancer immunotherapies, which relies on outside financing to advance its programs. Because the warrants carry a 19.9% beneficial ownership limitation, the excess was converted to pre-funded warrants, a structure that lets the investor hold a larger stake without breaching that cap.

The exercise price of $0.22 per share and the 19.9% beneficial ownership limitation define the transaction's terms, while pre-funded warrants priced at $0.00033 per share carry no expiration date. The shares issued upon exercise have not been registered under the Securities Act of 1933.

The players

PDS Biotechnology

PDS Biotechnology is a clinical-stage biotechnology company developing cancer immunotherapies, including its PDS0101 and PDS0301 candidates.

NantWorks

NantWorks is the investment and technology affiliate of NantHealth founder Patrick Soon-Shiong, which holds the warrants.

The details

NantWorks exercised its warrants in accordance with their terms, converting the portion exceeding the beneficial ownership limit into pre-funded warrants that do not expire. The company announced the exercise through a GlobeNewswire press release.

Timeline

  1. September 14, 2026: private placement initially closed, generating about $11.3 million in gross proceeds.

  2. November 10, 2026: NantWorks' warrant exercise announced.

Market Landscape

The financing structure, with pre-funded warrants used to keep an investor under a 19.9% ownership cap, lets small clinical-stage biotechs raise capital without triggering dilution limits. Funding from a large affiliated holder also positions PDS Biotechnology to pursue Phase 3 development through strategic partnerships.

For shareholders, the exercise dilutes existing holders while adding roughly $3.9 million to the company's cash. Investors weighing exposure to clinical-stage oncology should note that the new shares are unregistered and subject to resale restrictions.

The takeaway

Warrant structures with pre-funded components let early-stage companies raise money while managing ownership limits, a mechanism worth tracking when reviewing biotech financings. Investors should check whether the shares they receive are registered before assuming liquidity.

Further reading

Explore more Biotech coverage for context on how drug developers are financing late-stage trials.